{"title":"Fat Burn","description":null,"products":[{"product_id":"slu-pp-332-10mg","title":"SLU-PP-332 10mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eSLU-PP-332\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExperimental Exercise Mimetic | Metabolic Research Compound\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSLU-PP-332\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, also known as \u003c\/span\u003e\u003cem\u003e\u003cspan\u003eSLUPP\u003c\/span\u003e\u003c\/em\u003e\u003cspan\u003e, is an experimental small-molecule compound being investigated for its potential effects on energy metabolism, fat oxidation, and skeletal muscle endurance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOften described as an \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e“exercise mimetic,”\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e SLU-PP-332 is a synthetic agonist of the estrogen-related receptors \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eERRα, ERRβ, and ERRγ\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, which play important roles in mitochondrial function, cellular energy regulation, and oxidative metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnlike conventional stimulants, SLU-PP-332 targets metabolic pathways associated with aerobic exercise, making it an emerging subject of interest in preclinical metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSLU-PP-332 activates estrogen-related receptor signaling pathways involved in regulating cellular energy production and metabolic adaptation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePreclinical research suggests that this activation may:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnhance oxidative metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Promote pathways involved in mitochondrial energy production.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIncrease fat oxidation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Support greater utilization of fatty acids as an energy source in experimental models.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImprove muscular endurance:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influence skeletal muscle metabolism in ways associated with aerobic training adaptations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIncrease energy expenditure:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Activate metabolic processes associated with higher energy consumption.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSupport metabolic research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Provide a potential research pathway for investigating obesity, metabolic dysfunction, and muscle-related conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese effects have been investigated in preclinical models and have not been established in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePreclinical Research Findings\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAnimal studies investigating SLU-PP-332 have reported promising results, including:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eApproximately 12% reduction in fat mass\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e in certain obese mouse models over a four-week period.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNearly 50% improvement in endurance performance\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e under specific experimental conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImproved glucose tolerance\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e and metabolic parameters in studied animals.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnhanced skeletal muscle oxidative metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, suggesting adaptations resembling certain effects of endurance exercise.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e These findings are based on animal experiments. They should not be interpreted as evidence of equivalent benefits in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSLU-PP-332 is being investigated in research involving:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eEstrogen-related receptor signaling\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eMitochondrial function and energy metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSkeletal muscle oxidative adaptations\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eObesity and metabolic dysfunction\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eExercise-mimetic pharmacology\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eGlucose homeostasis and fatty acid metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eSafety \u0026amp; Regulatory Status\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSLU-PP-332 is an experimental research compound and is not approved for human consumption or therapeutic use.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHuman clinical safety and efficacy have not been established. Its toxicity profile, pharmacokinetics, appropriate dosing, potential adverse effects, and long-term consequences in humans remain insufficiently characterized.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAnimal research does not establish that SLU-PP-332 can safely replace physical exercise. Exercise provides additional cardiovascular, skeletal, psychological, and physiological benefits that have not been demonstrated with this compound.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR LABORATORY RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot for human or veterinary use. Not for ingestion, injection, or self-administration. Not intended to diagnose, treat, cure, or prevent any disease.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan\u003ePEPTITAN — Precision. Science. Research.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501710508296,"sku":null,"price":180.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"kpv-30mg","title":"KPV 30mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eKPV — Experimental Tripeptide for Anti-Inflammatory Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eKPV is a synthetic tripeptide composed of three amino acids: lysine, proline, and valine (Lys-Pro-Val).\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH) and has attracted scientific interest for its potential anti-inflammatory properties, particularly in research involving intestinal inflammation and immune cell signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePreclinical studies have investigated KPV's effects on inflammatory pathways in laboratory cell cultures and animal models of intestinal inflammation. However, its safety and efficacy in humans have not been established through clinical trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProposed Mechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eKPV is being investigated for its potential ability to modulate inflammatory signaling pathways and cellular immune responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInflammatory Signaling:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Laboratory studies suggest that KPV may inhibit the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways under certain experimental conditions, potentially reducing the production of specific pro-inflammatory mediators.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide Transport:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research indicates that KPV may be transported into intestinal epithelial cells and certain immune cells through the peptide transporter PepT1, potentially contributing to its observed biological activity in experimental models.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImmune Response Modulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Preclinical findings suggest that KPV may influence inflammatory responses in selected cellular and animal models. Its precise molecular mechanisms and relevance to human physiology remain under investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003ePreclinical Research Findings\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe available scientific evidence concerning KPV is predominantly preclinical.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCellular Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Laboratory experiments involving intestinal epithelial cells and immune cell models have examined KPV's influence on inflammatory signaling and the release of pro-inflammatory cytokines.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAnimal Studies:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research involving mouse models of experimentally induced colitis has reported reductions in inflammatory markers and histological signs of intestinal inflammation following KPV administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLimited Clinical Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e There is currently insufficient clinical evidence to establish the safety or effectiveness of KPV for treating inflammatory conditions in humans. Its pharmacokinetic characteristics, optimal administration methods, and long-term safety profile have not been adequately determined.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eKPV is being explored across several areas of experimental biomedical research:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIntestinal Inflammation Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of molecular pathways associated with inflammatory responses in the gastrointestinal tract.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInflammatory Signaling Pathways:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Examination of NF-κB and MAPK regulation and their involvement in pro-inflammatory mediator production.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePeptide Transport Mechanisms:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Exploration of the role of PepT1 in cellular peptide uptake and the biological activity of short-chain peptides.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImmune Cell Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of interactions between small peptides, intestinal epithelial cells, and immune system responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese applications represent \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eexperimental research areas rather than established therapeutic indications\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCurrent evidence does not establish KPV as an effective treatment for inflammatory bowel disease, autoimmune disorders, skin conditions, or other inflammatory diseases in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eDevelopment Status \u0026amp; Safety Considerations\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eKPV remains an \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eexperimental research peptide and is not an approved medication for routine clinical use\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAvailable regulatory assessments have not identified sufficient human clinical trial or exposure data to establish its safety and efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eImportant safety considerations include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUnestablished Human Safety:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e There is insufficient clinical evidence to determine the risks associated with human exposure.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLimited Pharmacokinetic Data:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Human absorption, distribution, metabolism, and elimination have not been adequately characterized.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUnknown Immunogenicity:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e The potential for immune-related adverse reactions remains insufficiently studied.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUncertain Long-Term Effects:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Long-term toxicity and potential adverse effects in humans remain unknown.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eFindings from laboratory and animal studies cannot reliably predict clinical outcomes in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate laboratory and scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot for human or veterinary use. Not intended for ingestion, injection, self-administration, or any form of clinical application.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNot intended to diagnose, treat, cure, or prevent any disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501835157768,"sku":null,"price":160.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"cbl514-20mg","title":"CBL514 20mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eCBL-514 — Investigational Injectable for Targeted Fat Reduction\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFirst-in-Class Small-Molecule Drug Candidate | Adipocyte Apoptosis | Localized Adipose Tissue Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCBL-514 is a first-in-class investigational injectable small-molecule drug candidate developed by Caliway Biopharmaceuticals for the targeted reduction of localized subcutaneous fat.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eUnlike conventional weight-management strategies, such as dietary modification, physical exercise, or incretin-based medications including semaglutide and tirzepatide, CBL-514 is designed to act directly on adipose tissue by inducing \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eadipocyte apoptosis — the programmed death of fat cells\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis targeted mechanism represents a distinct experimental approach to localized fat reduction, with potential applications in non-surgical body contouring and adipose tissue research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is administered through localized subcutaneous injections under investigational clinical protocols. Its clinical effectiveness, tissue selectivity, durability of response, and long-term safety remain under evaluation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is being developed to induce programmed cell death in targeted adipocytes, potentially reducing localized fat tissue volume.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts proposed mechanism involves three principal areas of investigation:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdipocyte Apoptosis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CBL-514 is designed to activate biological processes associated with programmed fat cell death. The precise contribution of individual molecular pathways continues to be evaluated through scientific research.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTargeted Subcutaneous Fat Reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e By inducing apoptosis in adipocytes within the treated region, CBL-514 aims to reduce localized subcutaneous fat volume. However, the elimination of targeted fat cells does not guarantee permanent cosmetic results, as remaining adipocytes may enlarge and adipose tissue can accumulate again.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTissue Selectivity and Local Tolerability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Available preclinical and clinical findings suggest potentially favorable local tolerability under studied conditions. Further investigation is required to fully characterize tissue selectivity, systemic exposure, rare adverse events, and long-term safety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch Focus:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CBL-514 is being investigated as a localized adipose tissue intervention rather than a conventional appetite-suppressing or systemic weight-loss medication.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Trial Findings\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 has been evaluated in clinical trials investigating non-surgical subcutaneous fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch findings reported in connection with the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting included the following results.\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003cspan\u003eResearch Parameter\u003c\/span\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cspan\u003eReported Clinical Findings\u003c\/span\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eSubcutaneous Fat Reduction\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eIn a Phase 2 study, 69.6% of CBL-514-treated participants achieved a reduction of at least 150 mL of subcutaneous fat in the treated area at the eight-week assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003ePlacebo Comparison\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eNo participants in the placebo group achieved the same reduction threshold at the eight-week assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat — Initial Follow-Up\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eIn an MRI-assessed subgroup of Phase 2 trial participants, mean visceral adipose tissue volume decreased by 12.01% from baseline.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat — Subsequent Follow-Up\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eMean visceral adipose tissue volume remained 10.45% below baseline at the later assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat — Placebo Group\u003c\/span\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eMean visceral adipose tissue volume increased by 5.68% at the initial follow-up and by 11.76% at the subsequent assessment.\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eClinical Interpretation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese reported findings suggest that CBL-514 may have measurable effects on adipose tissue volume in selected clinical trial populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, the visceral fat results were derived from a subgroup of participants with available MRI measurements. They should therefore be considered \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003epreliminary clinical findings rather than definitive evidence of efficacy\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eLarger controlled studies are necessary to establish the reproducibility, clinical relevance, durability, and safety of these observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Clinical Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is being investigated across several areas of adipose tissue biology and therapeutic development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e1. Localized Subcutaneous Fat Reduction\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigation of CBL-514 as a non-surgical approach to reducing localized subcutaneous fat deposits, particularly in abdominal regions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough potentially relevant to aesthetic medicine, CBL-514 has not been established or approved as an alternative to liposuction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e2. Visceral Adipose Tissue Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExploration of whether CBL-514 may influence visceral adipose tissue volume.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePreliminary MRI findings have generated scientific interest, but additional controlled studies are required to confirm these observations and determine their clinical significance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e3. Combination Research with Incretin-Based Therapies\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePreclinical investigations have explored the combination of CBL-514 with tirzepatide, a dual GIP\/GLP-1 receptor agonist.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAnimal research has suggested potential effects on weight reduction and weight regain following treatment discontinuation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA Phase 2 clinical development program is investigating this combination. The proposed benefits have not yet been established in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e4. Cellulite and Other Adipose Tissue Conditions\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch programs have also explored CBL-514 for additional adipose tissue-related indications, including cellulite.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA separate formulation, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eCBL-514D\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, is under investigation for Dercum's disease, a rare disorder associated with painful fatty tissue deposits and lipomas.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese programs represent investigational applications and do not imply regulatory approval or established therapeutic effectiveness.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Development \u0026amp; Regulatory Status\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAs of October 2026, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eCBL-514 remained an investigational pharmaceutical candidate without regulatory approval for routine clinical use or commercial distribution as an approved medicine\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts global Phase 3 development program includes the \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eSUPREME-01 clinical trial\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, designed to evaluate the efficacy and safety of CBL-514 for non-surgical reduction of abdominal subcutaneous fat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRegulatory authorization will depend on the results of clinical development, comprehensive safety assessments, and review by the relevant regulatory authorities.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSafety \u0026amp; Tolerability\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eClinical studies reported to date have generally described CBL-514 as tolerable within the specific populations and treatment conditions evaluated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe most frequently reported adverse events have included temporary, mild-to-moderate injection-site reactions, such as:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eLocalized pain or discomfort\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSwelling at the injection site\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eRedness and temporary skin reactions\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese findings do not establish the absence of serious adverse events or confirm long-term safety.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant Safety Considerations\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInvestigational Status:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e CBL-514 has not been approved for routine therapeutic or aesthetic use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIncomplete Long-Term Safety Data:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Potential delayed adverse effects and long-term tissue responses remain under investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUncertain Durability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Permanent elimination of localized fat deposits has not been clinically established.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLimited Generalizability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical trial results may not apply to populations outside those studied.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdministration-Related Risks:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Injection procedures may involve additional risks that require evaluation and appropriate clinical oversight.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 should not be represented as an approved weight-loss medication, a proven substitute for liposuction, or a treatment capable of guaranteeing permanent localized fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eScientific Research \u0026amp; Development Perspective\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 represents an emerging investigational approach in adipose tissue pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy focusing on adipocyte apoptosis rather than appetite regulation or caloric intake, the compound introduces a different strategy for exploring localized fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough early clinical findings are encouraging, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eits therapeutic potential remains dependent on successful clinical development, confirmation of meaningful clinical benefits, and comprehensive safety evaluation\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCBL-514 is an investigational pharmaceutical compound intended for use exclusively within legitimate scientific research and appropriately authorized clinical investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot approved for general human or veterinary use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot intended for personal injection or self-administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot intended for unsupervised aesthetic or weight-loss procedures.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot authorized for routine clinical treatment or commercial therapeutic use.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eNot established as safe or effective for diagnosing, treating, curing, or preventing any disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eThe designation “Research Use Only” does not replace applicable pharmaceutical regulations, clinical trial authorization requirements, or legal restrictions governing investigational medicines.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cspan\u003eScientific information provided for educational and research purposes. Clinical findings are preliminary and should be interpreted in the context of their original study designs, patient populations, and published evidence.\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501892665608,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"aod9604-10mg","title":"AOD9604 10Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eAOD-9604 — Experimental Peptide for Fat Metabolism Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHuman Growth Hormone Fragment | Lipolysis Research | Metabolic Investigation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (HGH), corresponding to amino acid residues 176–191.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOriginally developed as an investigational compound for obesity management, AOD-9604 has attracted scientific interest for its potential effects on lipid metabolism, particularly the regulation of fat breakdown and fat storage.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe peptide was designed to investigate whether certain metabolic actions associated with human growth hormone could be separated from its growth-promoting effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProposed Mechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAOD-9604 has been studied for its potential influence on two important metabolic processes:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLipolysis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e The breakdown of stored triglycerides within adipose tissue, releasing fatty acids that may subsequently be used for energy.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLipogenesis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e The biological process through which the body synthesizes and stores fat. Preclinical research has investigated whether AOD-9604 can influence this process.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone-Related Metabolic Signaling:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e AOD-9604 was developed to explore selected fat-metabolism effects associated with HGH without reproducing its full growth-promoting activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research has investigated whether AOD-9604 can influence lipid metabolism without the same effects on blood glucose regulation associated with full-length growth hormone.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese proposed mechanisms are based primarily on experimental findings and do not establish clinically meaningful fat loss in humans.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePreclinical \u0026amp; Clinical Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAOD-9604 has been investigated in laboratory studies, animal models, and human clinical trials involving obesity and metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEarly preclinical findings suggested possible effects on fat metabolism. However, subsequent clinical development did not establish sufficient weight-loss efficacy to support its approval as an obesity treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts potential effects on body composition, long-term metabolic function, and safety remain insufficiently established for clinical use.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAOD-9604 has been studied in several areas of metabolic research:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLipid Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of biological pathways involved in fat breakdown and storage.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdipose Tissue Biology:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Exploration of metabolic responses in fat cells.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHuman Growth Hormone Fragment Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Examination of the biological activity of selected HGH-derived peptide sequences.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eObesity Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of experimental approaches to regulating adipose tissue metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose and Metabolic Signaling:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Study of potential interactions between lipid metabolism and glucose regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese are experimental research applications, not established therapeutic indications.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eDevelopment Status \u0026amp; Safety\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAOD-9604 is an investigational peptide and is not approved as a medication for obesity treatment or routine human use.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough it has undergone human clinical investigation, its safety and effectiveness for weight management have not been established to the standard required for regulatory approval.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePotential concerns include insufficient long-term safety data, uncertainties regarding different administration routes, and limited evidence supporting clinically meaningful reductions in body fat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAOD-9604 should not be presented as a proven fat-burning treatment or as a safe alternative to approved weight-management therapies.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate laboratory and scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot for human or veterinary use. Not intended for ingestion, injection, self-administration, or therapeutic application.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNot intended to diagnose, treat, cure, or prevent any disease.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501920780552,"sku":null,"price":150.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"ret4trutid3-40mg","title":"Ret4trutid3 40Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eRETATRUTIDE — Investigational Triple Receptor Agonist for Metabolic Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdvanced Metabolic Research | GLP-1, GIP \u0026amp; Glucagon Receptor Agonist | Obesity \u0026amp; Type 2 Diabetes Investigation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutide is an innovative, first-in-class investigational peptide developed by Eli Lilly, designed to simultaneously activate three key metabolic hormone receptors: GLP-1, GIP, and glucagon.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis triple receptor agonist is being investigated for its potential applications in obesity management, type 2 diabetes, and metabolic disorders.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy targeting multiple pathways involved in appetite regulation, glucose metabolism, energy expenditure, and metabolic homeostasis, retatrutide represents an emerging approach to metabolic pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eRetatrutide combines three complementary hormonal mechanisms within a single molecule.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGLP-1 Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influences appetite regulation, promotes satiety, and supports glucose-dependent insulin secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGIP Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Participates in glucose-dependent insulin regulation and metabolic signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucagon Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influences hepatic energy metabolism and may contribute to increased energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIntegrated Metabolic Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Simultaneous activation of these pathways is being investigated for its combined effects on body weight, glycemic control, and energy homeostasis.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Findings\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eRetatrutide has demonstrated substantial weight reduction in clinical trials, including advanced Phase III studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReported findings include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eUp to 24.2% mean body weight reduction after 48 weeks\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e in a Phase II trial involving participants receiving the highest studied dose.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e28.3% average weight reduction over 80 weeks\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e in the Phase III TRIUMPH-1 study among participants receiving the 12 mg investigational dose.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImproved glycemic control\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e in studies involving adults with type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eContinued investigation of cardiometabolic outcomes\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, including obesity-related complications and metabolic health.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese results were obtained under controlled clinical trial conditions and should not be interpreted as guaranteed outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eObesity Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of hormonal pathways involved in body weight regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eType 2 Diabetes Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Evaluation of glucose metabolism, insulin response, and glycemic control.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnergy Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Exploration of interactions between appetite, energy intake, and energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Pharmacology:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research into the combined biological effects of GLP-1, GIP, and glucagon receptor activation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiometabolic Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of obesity-associated metabolic complications.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese represent active areas of clinical investigation rather than approved therapeutic indications.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Development \u0026amp; Safety\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAs of November 2026, \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eretatrutide remains an investigational pharmaceutical candidate undergoing advanced clinical development and has not received regulatory approval for general clinical use.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCommonly reported adverse events in clinical trials have included gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Its complete long-term safety profile remains under evaluation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough clinical findings are promising, retatrutide's clinical use requires appropriate regulatory authorization and further assessment of its benefits and risks.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations and appropriately authorized clinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot approved for general human or veterinary use. Not intended for personal injection, self-administration, or unsupervised therapeutic applications.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNot intended for routine diagnosis, treatment, cure, or prevention of disease outside authorized clinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe designation “Research Use Only” does not constitute authorization to manufacture, distribute, or administer an investigational medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501947552008,"sku":null,"price":500.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"ret4trutide-20mg","title":"Ret4trutide 20Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eRETATRUTIDE — Advanced Triple Receptor Agonist for Metabolic Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInvestigational Peptide | GLP-1, GIP \u0026amp; Glucagon Receptor Agonist | Obesity \u0026amp; Metabolic Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutide is an innovative investigational peptide developed by Eli Lilly that simultaneously targets three metabolic hormone receptors: GLP-1, GIP, and glucagon.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis triple receptor agonist is being investigated for its potential in obesity management, type 2 diabetes, and metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy activating multiple hormonal pathways involved in appetite control, glucose metabolism, and energy expenditure, retatrutide represents an emerging approach to metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eRetatrutide combines three complementary mechanisms:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGLP-1 Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influences appetite regulation, increases satiety, and supports glucose-dependent insulin secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGIP Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Contributes to glucose regulation and metabolic signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucagon Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influences hepatic energy metabolism and may contribute to increased energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e The combined activation of these receptors is being investigated for its effects on body weight, glucose control, and energy balance.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Findings\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eClinical investigations have reported substantial weight reduction in selected study populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn a Phase II trial, participants receiving the highest studied dose achieved an \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eaverage body weight reduction of up to 24.2% over 48 weeks\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings have supported further investigation through advanced Phase III clinical trials.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, trial results should not be interpreted as guaranteed individual outcomes or definitive proof of superiority over all currently available weight-management treatments.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eObesity Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of metabolic and hormonal pathways involved in body weight regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eType 2 Diabetes Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Evaluation of glucose homeostasis and insulin-related metabolic responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnergy Expenditure:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Exploration of metabolic processes associated with energy utilization.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAppetite Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research into hormonal mechanisms affecting hunger and satiety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Health:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of obesity-related metabolic complications.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eDevelopment Status \u0026amp; Safety\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutide remains an investigational pharmaceutical compound undergoing advanced clinical development, including Phase III trials.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is not approved for routine clinical use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eReported adverse events in clinical studies have commonly included gastrointestinal symptoms such as nausea, vomiting, and diarrhea.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFurther research is required to fully establish its long-term safety, effectiveness, and benefit-risk profile across different patient populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations and appropriately authorized clinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot approved for general human or veterinary use. Not intended for personal injection, self-administration, or unsupervised therapeutic applications.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-use labeling does not replace applicable regulatory authorization requirements.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59501988249864,"sku":null,"price":300.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"tirz3patid4-20mg","title":"Tirz3patid4 20Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eTIRZEPATIDE — Dual GIP \u0026amp; GLP-1 Receptor Agonist\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdvanced Metabolic Research | Glucose Regulation | Weight Management\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTirzepatide is a synthetic peptide and dual receptor agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDeveloped by Eli Lilly and commercially available as \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eMounjaro®\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, tirzepatide is an approved once-weekly injectable prescription medicine used for the management of type 2 diabetes and, in eligible adults, obesity or overweight accompanied by weight-related health conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts dual-action mechanism has attracted significant scientific interest due to its effects on appetite regulation, glucose metabolism, insulin secretion, and body weight.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts through two complementary metabolic pathways:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGIP Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Enhances glucose-dependent insulin secretion and contributes to metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGLP-1 Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Promotes satiety, reduces appetite, supports insulin secretion, and influences gastric emptying.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Helps regulate blood glucose levels through glucose-dependent hormonal mechanisms.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBody Weight Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Reduced appetite and energy intake can contribute to substantial weight reduction in eligible patients.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eClinical studies have demonstrated significant improvements in glycemic control and body weight among studied populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eKey research areas include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eType 2 Diabetes:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation and clinical management of blood glucose regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eObesity and Weight Management:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Evaluation of body weight reduction and long-term weight maintenance.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAppetite Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Examination of incretin-related signaling pathways involved in hunger and satiety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Health:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research into insulin sensitivity, energy balance, and cardiometabolic risk factors.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eRegulatory Status \u0026amp; Safety\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTirzepatide is an approved prescription medicine in the European Union, including Portugal, for specific clinical indications.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eApproved medicinal products are subject to pharmaceutical manufacturing standards, quality controls, and regulatory oversight.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCommon adverse reactions include nausea, diarrhea, vomiting, constipation, and other gastrointestinal symptoms. More serious risks and precautions are described in the official prescribing information.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe safety, purity, and effectiveness of independently manufactured or research-labeled tirzepatide preparations cannot be assumed to be equivalent to those of approved medicines.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR LEGITIMATE SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch materials are intended exclusively for qualified professionals conducting authorized scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch-labeled preparations are not approved medicinal products and must not be used for human or veterinary administration, personal injection, or self-medication.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA “Research Use Only” designation does not override pharmaceutical regulations or authorize the commercial supply of an unapproved injectable medicine for human use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59502020821256,"sku":null,"price":250.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"l-carnitina-1200mg-ml-10ml","title":"L-Carnitina 1200mg\/ML 10ML","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eL-CARNITINE — Advanced Fatty Acid Metabolism \u0026amp; Performance Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnergy Metabolism | Mitochondrial Function | Exercise Recovery | Metabolic Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eL-Carnitine is a naturally occurring amino acid-derived compound that plays an essential role in cellular energy metabolism by transporting long-chain fatty acids into the mitochondria, where they can be oxidized to produce energy.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eWidely studied in sports nutrition, exercise physiology, and metabolic research, L-Carnitine contributes to the body's ability to utilize fatty acids as an energy source.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough frequently marketed as a fat-burning supplement, its scientific applications extend beyond weight management, including mitochondrial function, exercise recovery, and cellular energy regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine participates in several important physiological processes:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFatty Acid Transport:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Facilitates the movement of long-chain fatty acids into mitochondria through the carnitine shuttle system.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMitochondrial Energy Production:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Supports fatty acid oxidation, an essential process in cellular ATP production.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Helps maintain the balance between free coenzyme A and acyl-CoA compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExercise Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Plays a physiological role in energy utilization during physical activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCellular Function:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Participates in metabolic pathways important for skeletal muscle, cardiac tissue, and other energy-demanding organs.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eExercise Performance \u0026amp; Recovery Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine has been investigated for its potential effects on athletic performance, fatigue, and post-exercise recovery.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMuscle Recovery:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Some studies suggest that supplementation may reduce certain markers of exercise-induced muscle damage and delayed-onset muscle soreness.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExercise-Related Fatigue:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research has explored potential effects on fatigue and exercise tolerance, although findings remain inconsistent.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMuscle Glycogen Utilization:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Certain experimental conditions have suggested changes in substrate utilization, but consistent glycogen-sparing benefits have not been established.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Efficiency:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e L-Carnitine supports normal fat metabolism, although supplementation does not necessarily increase fat oxidation or physical performance in healthy individuals.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eScientific Perspective:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Results vary according to supplementation protocols, baseline carnitine status, training characteristics, and individual physiology.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eCognitive \u0026amp; Neurological Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAcetyl-L-Carnitine (ALCAR), a related form of carnitine, has been investigated for neurological and cognitive applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch areas include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCognitive Function:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of memory, attention, and cognitive performance.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMitochondrial Brain Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Exploration of neuronal energy regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAge-Related Cognitive Changes:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research into potential effects on cognitive decline in selected populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMental Fatigue:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Evaluation of potential effects on fatigue-related symptoms.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eAlthough some studies have reported encouraging findings, evidence remains insufficient to establish consistent cognitive benefits or prevention of neurodegenerative conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eCardiovascular \u0026amp; Cellular Health Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine has also been studied in relation to cardiovascular metabolism and cellular protection.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiac Energy Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Supports normal fatty acid utilization in cardiac muscle.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eOxidative Stress:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Some investigations have reported changes in oxidative stress biomarkers.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInflammatory Markers:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical research has examined potential effects on selected inflammatory biomarkers.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiovascular Outcomes:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Studies have explored possible benefits in specific cardiac conditions, but the available evidence does not establish L-Carnitine as a proven treatment for preventing heart attacks or reducing cardiovascular mortality.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eL-Carnitine \u0026amp; Fat Loss: Understanding the Evidence\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine is frequently promoted as a powerful fat-burning compound. However, scientific findings require a more balanced interpretation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFat Metabolism Is Not the Same as Fat Loss\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAlthough L-Carnitine is essential for transporting fatty acids into mitochondria, increasing carnitine intake does not automatically increase body fat oxidation or produce significant weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eWeight Management:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Some clinical reviews have reported modest average weight reductions with supplementation, although results vary significantly.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnergy Balance:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Sustained weight reduction generally depends on overall energy balance rather than carnitine supplementation alone.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExercise Interaction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Physical activity can increase energy expenditure, but it does not guarantee that additional L-Carnitine will enhance fat loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIndividual Variability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Age, nutritional status, metabolic health, and baseline carnitine concentrations may influence responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eKey Scientific Finding:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e L-Carnitine is essential for normal fatty acid metabolism, but it should not be considered a clinically proven rapid fat-loss solution.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eMitochondrial energy metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eFatty acid transport and oxidation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eSkeletal muscle physiology\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eExercise recovery and fatigue\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eCellular oxidative stress\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eCardiovascular energy metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eCognitive and neurological metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eBody composition and weight-management research\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eSafety \u0026amp; Research Considerations\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine is naturally present in the human body and is also available in approved medicinal formulations and dietary supplements, depending on the product and jurisdiction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, safety depends on the formulation, dosage, route of administration, individual health status, and intended application.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePotential adverse effects of supplementation may include gastrointestinal discomfort, nausea, diarrhea, and a characteristic fish-like body odor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch has also examined the conversion of dietary carnitine into trimethylamine N-oxide (TMAO) by intestinal microbiota and its possible relationship with cardiovascular risk. The clinical significance of this association remains under investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY — WHEN SUPPLIED AS A RESEARCH-GRADE MATERIAL.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended for qualified professionals conducting legitimate scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-grade preparations are not automatically suitable for human or veterinary administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot intended for personal injection, self-administration, or unauthorized therapeutic applications.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-use labeling does not replace applicable product safety requirements or pharmaceutical regulations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59502039630088,"sku":null,"price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"l-carnitina-500mg-ml-10ml","title":"L-Carnitina 500mg\/ML 10ML","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eL-CARNITINE — Physical Performance, Recovery \u0026amp; Metabolic Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExercise Physiology | Mitochondrial Energy Production | Cognitive Function | Fat Metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePhysical Performance \u0026amp; Exercise Recovery\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine plays an essential role in mitochondrial energy metabolism and has been extensively investigated for its potential effects on physical performance, muscle recovery, and exercise-induced fatigue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMuscle Fatigue:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Some clinical studies suggest that L-Carnitine supplementation may influence fatigue-related markers and exercise tolerance. However, evidence of consistent reductions in muscular fatigue or lactate accumulation remains mixed.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePost-Exercise Recovery:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research indicates that L-Carnitine may help reduce certain markers of exercise-induced muscle damage and delayed-onset muscle soreness in specific populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMuscle Glycogen Preservation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Experimental studies have investigated whether changes in fatty acid metabolism could influence glycogen utilization during exercise. Consistent glycogen-sparing effects from supplementation have not been established.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEnergy Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria, supporting their oxidation for cellular energy production.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eCognitive Health \u0026amp; Nervous System Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAcetyl-L-Carnitine (ALCAR), a related form of L-Carnitine, has been investigated for its potential neurological and cognitive applications.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFocus \u0026amp; Memory:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e ALCAR can cross the blood-brain barrier and has been studied for its possible effects on memory, attention, and neuronal energy metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNeuroprotective Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Preclinical investigations have explored its potential influence on mitochondrial function and neuronal responses to oxidative stress.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAge-Related Cognitive Function:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Certain clinical studies have suggested possible cognitive benefits in selected older populations, although evidence remains insufficient to establish prevention of cognitive decline.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMental Fatigue:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research has explored possible effects on mental fatigue, but consistent improvements have not been conclusively demonstrated.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eCardiovascular \u0026amp; General Health Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine is involved in normal cardiac energy metabolism and has been investigated for its potential role in cardiovascular and cellular health.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiac Energy Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e L-Carnitine supports the transport and oxidation of fatty acids, an important energy source for heart muscle.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiovascular Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical investigations have evaluated L-Carnitine in conditions such as angina and recovery following myocardial infarction. However, current evidence does not establish a reliable reduction in post-heart-attack mortality.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAntioxidant Activity:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Some studies have reported improvements in selected oxidative stress biomarkers following supplementation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInflammatory Response:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research has investigated potential effects on certain inflammatory markers, although findings vary between studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eThe Fat-Loss Myth: What Does the Science Say?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eL-Carnitine is frequently marketed as a powerful fat-burning supplement. However, its essential physiological role in fatty acid metabolism does not automatically translate into significant body fat reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFat Transport vs. Fat Loss:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e L-Carnitine helps transport fatty acids into mitochondria, but additional supplementation does not necessarily increase fat oxidation or accelerate weight loss in healthy individuals.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eExercise \u0026amp; Energy Balance:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Sustained fat loss generally requires an appropriate energy balance. Exercise can increase energy expenditure, but it does not guarantee that L-Carnitine supplementation will produce additional fat loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMixed Scientific Evidence:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Systematic reviews and meta-analyses have reported modest average weight reductions in some populations, with considerable variation between individuals and study designs.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIndividual Metabolic Differences:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Baseline carnitine status, age, nutritional status, metabolic health, and supplementation protocols may influence research outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eScientific Conclusion:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e L-Carnitine is essential for normal fat metabolism, but it is not a proven rapid fat-loss solution. Its potential effects on exercise recovery, metabolic function, and body composition require interpretation within the context of available scientific evidence.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-grade preparations are not automatically suitable for human or veterinary administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eNot intended for self-administration, unauthorized therapeutic applications, or use as an unapproved injectable preparation.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-use designation does not replace applicable pharmaceutical regulations or product safety requirements.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59502057226504,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"tirz3patid4-40mg","title":"Tirz3patid4 40Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eTIRZEPATIDE — Advanced Dual GIP \u0026amp; GLP-1 Receptor Agonist\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research | Glucose Regulation | Weight Management | Incretin-Based Therapy\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTirzepatide is a synthetic peptide and dual GIP\/GLP-1 receptor agonist developed by Eli Lilly and marketed under the brand name Mounjaro®.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is an approved once-weekly injectable prescription medication in Portugal and the European Union for the treatment of type 2 diabetes and weight management in eligible patients with obesity or overweight accompanied by weight-related health conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide simultaneously activates two important metabolic hormone receptors: \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eglucose-dependent insulinotropic polypeptide (GIP)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e and \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eglucagon-like peptide-1 (GLP-1)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThrough this dual mechanism, tirzepatide influences insulin secretion, appetite regulation, satiety, and energy intake, making it an important subject of metabolic and pharmaceutical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGIP Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Enhances glucose-dependent insulin secretion and contributes to metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGLP-1 Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Promotes satiety, reduces appetite, and influences gastric emptying.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Supports blood glucose regulation through incretin-related mechanisms.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBody Weight Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Reduces food intake through effects on appetite and satiety, contributing to weight reduction in clinical studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Provides opportunities to investigate the interaction between incretin signaling, insulin function, and energy balance.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Scientific Evidence\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials have demonstrated significant reductions in body weight and improvements in glycemic control in selected patient populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch areas include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eType 2 Diabetes:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Glycemic control and glucose-dependent insulin responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eObesity \u0026amp; Weight Management:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Body weight reduction and long-term metabolic outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAppetite Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Hormonal pathways involved in hunger and satiety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Interactions between energy intake, glucose regulation, and insulin sensitivity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiometabolic Health:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of obesity-related metabolic complications.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eClinical outcomes depend on the population studied, treatment duration, and other individual factors.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eRegulatory Status \u0026amp; Safety\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTirzepatide is an approved prescription medication, but research-grade tirzepatide preparations are not automatically approved medicines.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCommon adverse reactions associated with approved tirzepatide treatment include nausea, diarrhea, vomiting, constipation, and abdominal discomfort.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMore serious risks and precautions require medical assessment and are described in the official prescribing information.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe quality, purity, safety, and effectiveness of independently manufactured research preparations cannot be assumed equivalent to those of authorized pharmaceutical products.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch-grade preparations are not intended for human or veterinary administration, personal injection, self-medication, or unauthorized therapeutic use.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe designation “Research Use Only” does not constitute authorization to manufacture, market, distribute, or administer an unapproved medicinal preparation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59502059225352,"sku":null,"price":400.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"},{"product_id":"tesamorelin-5mg","title":"Tesamorelin 5Mg","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003c\/p\u003e\n\u003ch1\u003e\u003cspan\u003eTESAMORELIN — Advanced Growth Hormone \u0026amp; Visceral Fat Research Peptide\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Analogue | Visceral Adipose Tissue | Growth Hormone Regulation | Metabolic Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTesamorelin is a synthetic peptide analogue of Growth Hormone-Releasing Hormone (GHRH), developed to stimulate endogenous growth hormone (GH) secretion and investigate its effects on visceral adipose tissue and metabolic regulation.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOriginally approved by the U.S. Food and Drug Administration (FDA) in 2010, tesamorelin is used in specific prescription formulations to reduce excess abdominal fat in adults living with HIV who have lipodystrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy activating growth hormone signaling pathways, tesamorelin influences the physiological processes involved in fat metabolism and endocrine regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts established clinical application is limited to a specific medical population, while other potential metabolic applications remain subjects of scientific investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eMechanism of Action\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin acts through the hypothalamic-pituitary growth hormone axis, influencing several important physiological processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGHRH Receptor Activation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Stimulates growth hormone-releasing hormone receptors in the anterior pituitary gland.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndogenous Growth Hormone Secretion:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Promotes the release of naturally produced GH through physiological endocrine signaling pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eIGF-1 Regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Increased GH secretion stimulates insulin-like growth factor 1 (IGF-1) production, an important mediator of growth hormone activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat Metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Influences metabolic pathways associated with abdominal visceral adipose tissue, contributing to reductions observed in clinical studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eEndocrine Homeostasis:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Provides a research model for understanding interactions between growth hormone secretion, lipid metabolism, and metabolic regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eClinical Research \u0026amp; Scientific Evidence\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin has been evaluated in controlled human clinical trials involving adults with HIV-associated abdominal lipodystrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical research has demonstrated:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eVisceral Fat Reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Significant reductions in visceral adipose tissue compared with placebo in the studied population.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAbdominal Fat Distribution:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Measurable improvements in excessive abdominal fat accumulation associated with HIV-related lipodystrophy.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGrowth Hormone Signaling:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Increased GH and IGF-1 concentrations consistent with its pharmacological mechanism.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research Findings:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigation of lipid parameters, glucose regulation, and other metabolic outcomes, with results varying across studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant Scientific Distinction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Tesamorelin is not an approved general weight-loss medication. Its demonstrated effect on visceral abdominal fat should not be interpreted as evidence of significant overall body weight reduction or effectiveness for cosmetic fat loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003ePotential Research Applications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e1. Visceral Adipose Tissue Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigation of biological pathways involved in the accumulation, regulation, and reduction of visceral abdominal fat.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e2. Growth Hormone Regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExamination of endogenous GH secretion and its relationship with pituitary endocrine function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e3. IGF-1 Signaling\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch into growth hormone-dependent IGF-1 production and its effects on metabolic physiology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e4. HIV-Associated Lipodystrophy\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical investigation of abnormal fat distribution and excess visceral adipose tissue in adults living with HIV.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e5. Lipid Metabolism\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eExploration of metabolic pathways associated with fatty acid utilization, triglyceride regulation, and adipose tissue function.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e6. Metabolic Health Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eInvestigation of interactions between visceral adiposity, insulin sensitivity, glucose homeostasis, and endocrine signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese areas include both established clinical research and ongoing experimental investigations. They do not represent additional approved therapeutic indications.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eRegulatory Status \u0026amp; Clinical Development\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTesamorelin received its initial FDA approval in 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFDA-authorized tesamorelin products include prescription formulations marketed under the EGRIFTA brand.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, regulatory approval of a specific pharmaceutical formulation does not extend automatically to independently manufactured or research-grade tesamorelin preparations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin is not approved in the United States for general obesity management, bodybuilding enhancement, or cosmetic weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the European Union, the marketing authorization application for EGRIFTA was withdrawn in 2012. FDA approval should therefore not be interpreted as European marketing authorization.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eSafety \u0026amp; Potential Adverse Effects\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAlthough tesamorelin has undergone human clinical investigation, its use requires appropriate medical assessment and monitoring.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePotential adverse effects and safety considerations include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eInjection-Site Reactions:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Localized redness, discomfort, or irritation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFluid Retention:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Possible swelling, joint discomfort, or peripheral edema.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eElevated IGF-1 Levels:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Increased circulating IGF-1 may require clinical monitoring.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose Intolerance:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Potential changes in glucose regulation, including an increased risk of diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHypersensitivity Reactions:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Allergic responses may occur.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMalignancy-Related Precautions:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Growth hormone and IGF-1 signaling require particular caution in patients with active or previous malignancies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLong-Term Cardiovascular Safety:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Long-term cardiovascular outcomes have not been fully established.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Evidence \u0026amp; Limitations\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eImportant scientific limitations include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eTesamorelin is not established as a treatment for general obesity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eReductions in visceral adipose tissue do not necessarily produce significant overall weight loss.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eImprovements in lipid parameters are not consistent across all studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eLong-term cardiovascular benefits have not been demonstrated.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eFat accumulation may return after treatment discontinuation.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan\u003eResearch-grade preparations cannot be assumed equivalent to FDA-approved pharmaceutical formulations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Use Only\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFOR SCIENTIFIC AND LABORATORY RESEARCH PURPOSES ONLY — WHEN SUPPLIED AS A RESEARCH-GRADE MATERIAL.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIntended exclusively for qualified professionals conducting legitimate scientific investigations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch-grade tesamorelin is not intended for human or veterinary administration, personal injection, self-medication, bodybuilding enhancement, or unauthorized therapeutic applications.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eResearch-use labeling does not constitute pharmaceutical approval or authorization for clinical administration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePEPTITAN — PRECISION. SCIENCE. RESEARCH.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":59502085013768,"sku":null,"price":140.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1078\/2942\/8488\/files\/Frasco_de_Vidro_com_Arcos_Dourados.png?v=1794657660"}],"url":"https:\/\/peptgrind.com\/collections\/fat-burn.oembed","provider":"peptitan","version":"1.0","type":"link"}